They often treat open source as a procurement issue instead of an ongoing governance obligation. The mistake is assuming component adoption ends the control problem, when the real challenge is ownership, patch coordination, and traceability across the device lifecycle. That is where security, safety, and compliance intersect.
Why open source is not just a procurement decision
In medical devices, open source is often treated as a one-time sourcing choice, then forgotten after integration. That framing is too narrow. Once a component is embedded, the device team inherits a continuing obligation to know what was shipped, who owns it, how it will be updated, and how changes are traced across design, verification, manufacturing, and field support.
The practical error is to treat the library or package as “done” once it passes initial approval. In reality, the risk surface changes as upstream maintainers patch bugs, disclose vulnerabilities, or change release practices. That is why open source belongs in device governance, not just vendor intake. The issue is lifecycle control, not merely component selection.
For teams managing software supply chain exposure, the open source question is closely related to upstream trust and release integrity. NHIMG’s LiteLLM PyPI package breach and Nx s1ngularity attack 2025 show how package ecosystems can turn routine dependency use into credential theft and downstream compromise.
What teams miss about ownership, patching, and traceability
Medical-device teams often assume that open source comes with an implicit maintenance model, but open source only gives access to source, not accountability for the device it ends up in. Someone still has to own vulnerability intake, decide whether a patch can be safely applied, and document how the change affects the device’s validated state. Without that owner, known issues linger long after the original integration work is finished.
Patch coordination is especially hard because device software is not updated in the same way as ordinary enterprise software. A fix may require regression testing, regulatory review, supplier coordination, or field-service planning before it can be deployed. That means a vulnerability can be technically easy to understand but operationally slow to remediate. Teams that ignore this gap often discover too late that the “free” component carried a real maintenance burden.
Traceability is the other common failure. If teams cannot map each open source component to its version, origin, dependencies, and affected device models, they cannot answer basic questions during an advisory or recall. NHIMG’s PyPI secrets exposure 2023 and SpotBugs token leak 2025 are reminders that upstream package and repository compromise can propagate far beyond the original maintainer.
Why the security, safety, and compliance problems converge
Open source in medical devices sits at the intersection of cybersecurity, patient safety, and regulated quality processes. A vulnerable component is not only an IT issue, because it can affect device availability, integrity, or behaviour in ways that matter clinically. At the same time, overreacting to every upstream disclosure without a change-control path can create unnecessary downtime or destabilise a validated build.
This is why the right response is governance that links software bills of materials, vulnerability monitoring, change control, and field remediation. The key question is not whether the code was open source, but whether the organisation can prove what it deployed, assess exposure quickly, and make a defensible decision about patching or mitigation. That same discipline is what regulators, auditors, and safety teams will expect when a component defect becomes a device issue.
Medical-device teams can also borrow lessons from broader healthcare identity and device governance. NHIMG’s Healthcare Identity Security Guide is useful because it connects medical device security with operational realities such as shared environments, third parties, and healthcare-specific oversight.
Risk and Threat Considerations
Open source creates exposure when teams assume upstream code is static or inherently trustworthy. In practice, compromised maintainers, poisoned packages, leaked publishing tokens, and delayed patching can turn a routine dependency into a supply-chain entry point that affects multiple device models or software releases.
Failure mechanism: Weak ownership or incomplete component traceability prevents teams from detecting which devices use a vulnerable package, while slow patch coordination leaves exposed code in the field after an upstream issue is known.
Impact: The result can be exploitability, unsupported device states, delayed remediation, safety risk, and compliance problems when the organisation cannot show control over the affected software.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 and CIS Controls v8 set the technical controls, while ISO/IEC 27001:2022 defines the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-53 Rev 5 | CM-8 — System Component Inventory | Open source in devices requires accurate component inventory and traceability. |
| SI-2 — Flaw Remediation | The issue centers on upstream fixes, patch timing, and remediation governance. | |
| Recommendation — Maintain a complete component inventory for each device build and release. Track vulnerabilities and apply validated remediation within defined timelines. | ||
| ISO/IEC 27001:2022 | A.8.8 — Management of technical vulnerabilities | Medical-device open source needs structured vulnerability handling across the lifecycle. |
| A.5.19 — Information security in supplier relationships | Open source dependencies create supplier-style governance obligations and upstream trust risk. | |
| Recommendation — Establish a vulnerability-management process for third-party and open source components. Define security requirements and oversight for externally sourced software components. | ||
| CIS Controls v8 | CIS-16 — Application Software Security | Open source in devices depends on secure acquisition, monitoring, and update practices. |
| Recommendation — Track third-party software and verify vulnerabilities are remediated before release. | ||
Practitioner Guidance
What to prioritise: Treat open source inventory as a living device-control record, not a software shopping list. The first priority is knowing which released devices contain which component versions and who owns the patch decision for each one.
What to verify: Before trusting a component, verify that you can trace it from source to shipped build, link it to a responsible owner, and explain the patch path if an upstream advisory lands tomorrow. If you cannot do that, you do not yet have governance, only adoption.
Decision rule: If the component can affect a clinical function, security control, or validated build, patching and mitigation must be handled through a device-lifecycle process, not ad hoc developer discretion. If the team cannot answer how a fix will be tested and documented, the real gap is process ownership, not code quality.
Practitioner takeaway: The mature posture is to manage open source in medical devices as an ongoing assurance problem, with traceability, patch coordination, and accountable ownership built into the device lifecycle from the start.
Related resources from NHI Mgmt Group
Deepen Your Knowledge
Free weekly newsletter
Subscribe to the NHI & AI Identity Journal
The latest on NHI and Agentic AI security – articles, research, breaches, news and events every week.
Bonus 33% off our NHI Course when you subscribe.
Reviewed and updated by the NHIMG editorial team on October 12, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org